An Oversupply Of COVID Antibody Treatments? Multiple Monoclonal Products Raise Potential For Errors

As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.

Molecular model of antibody taking part in immune defence. Molecule of immunoglobulin, 3D illustration
The US government is ready to begin allocation of Regeneron's casirivimab-imdevimab monoclonal antibody combination, which just received an EUA for use as a COVID-19 treatment. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet